InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
InterCure Ltd.NASDAQ: INCR
Net Income · Q2 FY2025 · quarter ended Jun 2025
Net income turns negative
Q2 FY2025 net income was -₪852K, compared with ₪716.5K a year earlier. Trailing-twelve-month net income was -₪70.93M.
Context
- Net income amounted to 13.6% of revenue in FY2025, down 16.9 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether next quarter's net income reaches the consensus estimate of ₪0, a +100.0% change from the same quarter last year.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- -₪852K+0.0% QoQ
- Last fiscal yearDec 2025
- -₪36.78M-49.5% YoY
- LTMJun 2025
- -₪70.93M+8.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -218.9% | +100.0% | +318.9 pp |
| 1 year | -49.5% | — | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
ILS · from the cash flow
- Latest · FY2025
- (36.78M) ILS
- Year-over-year change
- +49.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (36.78M) | +49.5% |
| FY2024 | 2024-12-31 | (72.79M) | -14.6% |
| FY2023 | 2023-12-31 | (63.53M) | -245.2% |
| FY2022 | 2022-12-31 | 43.75M | +499.7% |
| FY2021 | 2021-12-31 | 7.3M | — |
Net Income vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.1% is the 5th highest of 9, against a peer median of +9.1%.
- Net income amounts to 29.2% of revenue for INCR, versus a peer median of 66.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.15M USD | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $86.67M USD | -44.1% | -29.4% | 36.5% | |
| LTM Mar 2026 | $86.3M USD | +66.7% | — | 2193.7% | |
| LTM Jun 2025 | ₪70.93M ILS | +8.1% | — | 29.2% | |
| LTM Mar 2026 | $44.95M USD | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $39.95M USD | +162.9% | +13.7% | — | |
| LTM Mar 2026 | CA$36.38M CAD | +1.7% | +3.0% | — | |
| LTM Mar 2026 | $35.69M USD | +16.6% | — | 34.9% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.18M CAD | -73.6% | +21.9% | 66.4% |
| Peer median (excluding INCR) | — | +9.1% | -3.0% | 66.4% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.3M | 43.75M | (63.53M) | (72.79M) | (36.78M) |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| Deferred Income Tax | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Stock-Based Compensation | 6.45M | 8.91M | 2.59M | 2.28M | 2.43M |
| Change in Working Capital | (1.65M) | (3.02M) | (43.55M) | (9.19M) | 18.88M |
| Accounts Receivables | 8.39M | (18.29M) | (23.49M) | 13.26M | 9.29M |
| Inventory | (17.89M) | (75.99M) | 40.21M | (17.44M) | 15.95M |
| Accounts Payables | 2.79M | 57.03M | (47.63M) | (8.9M) | (8.82M) |
| Other Working Capital | 5.06M | 34.22M | (12.63M) | 3.88M | 2.46M |
| Other Non-Cash Items | (5.91M) | (10.16M) | 35.44M | 11.94M | 22.49M |
| Operating Cash Flow | 25.02M | 51.27M | (53.63M) | (66.93M) | 16.84M |
| Capital Expenditures | (14.03M) | (19.74M) | (2.62M) | (4.38M) | (3.55M) |
| Acquisitions (Net) | (19.09M) | (8.32M) | (4.2M) | 405K | 1.67M |
| Purchases of Investments | (1.25M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (30.84M) | (114.44M) | 11.59M | 21.66M | (107K) |
| Investing Cash Flow | (65.21M) | (142.5M) | 4.77M | 17.69M | (1.99M) |
| Debt Repayment | 65.83M | 137.73M | (61.98M) | 7.74M | (29.13M) |
| Common Stock Issued | 128.73M | 0 | 0 | 34M | 1.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.38M | (17.28M) | (20.91M) | (15.29M) | (19.03M) |
| Financing Cash Flow | 197.94M | 120.45M | (82.89M) | 26.46M | (46.66M) |
| Effect of Forex Changes | (4.54M) | 7.16M | 297K | (39K) | (44K) |
| Net Change in Cash | 158.33M | 36.37M | (131.45M) | (22.82M) | (31.85M) |
| Free Cash Flow | 10.99M | 31.53M | (56.25M) | (71.3M) | 13.29M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.